EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.

Authors

A. Dewdney

The Royal Marsden Hospital, Surrey, United Kingdom

A. Dewdney , J. Capdevila , B. Glimelius , A. Cervantes , D. M. Tait , G. Brown , A. Wotherspoon , D. Gonzalez de Castro , Y. J. Chua , R. Wong , Y. Barbachano , J. R. Oates , I. Chau , D. Cunningham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Gastrointestinal Cancers Symposium

bookmark_border

RAS mutations in expert-c, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).

First Author: Francesco Sclafani

insert_chart_outlined

Poster

2013 Gastrointestinal Cancers Symposium

bookmark_border

HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

First Author: Francesco Sclafani

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.

First Author: Wen Zhang

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).

First Author: Cynthia G. Leichman